Tricuspid valve replacement and levosimendan.
Isolated tricuspid valve replacement, which is not a common operation, is associated with poor short and long-term results, and the postoperative morbidity and mortality rates are high. The main reason for these adverse effects is the acute manifestation of chronic right heart failure. To treat right heart failure, we used levosimendan for its inotropic and vasodilatatory effects, and it does not increase the calcium overload in myocardial cells. We report two cases of tricuspid valve replacement operations performed using levosimendan. Both patients receiving levosimendan tolerated the operations well, and their postoperative courses were uneventful.
Cicekcioglu
Ferit
F
Cardiovascular Surgery Clinic, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey.
Parlar
Ali Ihsan
AI
Altinay
Levent
L
Yay
Kerem
K
Katircioglu
Salih Fehmi
SF
D000328:Adult; D000368:Aged; D002315:Cardiopulmonary Bypass; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003971:Diastole; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000627:therapeutic use*; D011724:Pyridazines / Q000008:administration & dosage / Q000627:therapeutic use*; D000077464:Simendan; D013599:Systole; D013997:Time Factors; D016896:Treatment Outcome; D014261:Tricuspid Valve / Q000601:surgery; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D014665:Vasodilator Agents; D000077464:Simendan